[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 4 (Autumn 2023) ::
Caspian J Intern Med 2023, 14(4): 741-745 Back to browse issues page
Association of metformin and aspirin intake with mammographic breast density: a cross-sectional study
Bita Eslami , Ramesh Omranipour , Arvin Aryan , Leila Bayani , Mahboubeh Abedi , Sadaf Alipour *
Breast Diseases Research Center, Cancer Institute, Tehran University of Medical Science, Tehran, Iran , sadafalipour@yahoo.com
Abstract:   (350 Views)
Background: Our purpose was to investigate the association between Mammographic breast density (MBD), a known strong marker for breast cancer and metformin and aspirin use and duration of use alone or simultaneously, in a sample of Iranian women considering other confounding factors.
Methods: In a cross-sectional study, 712 individuals were selected out of women referred to two university hospitals for screening mammography. Participants’ information was collected with a questionnaire. Four-category density scale (a = almost entirely fatty, b = scattered fibroglandular densities, c= heterogeneously dense, and d = extremely dense) was categorized as low (a&b) and high (c&d) density.
Results: The mean age of the participants was 49.80 ± 7.26 years. Sixty-five percent of women belonged to the high and 35% to the low MBD category. Both aspirin and metformin had a significantly negative association with MBD, however, when confounding factors were entered into the models, only aspirin after adjustment for age and BMI had an inverse association with MBD (OR = 0.53, 95% CI: 0.35-0.94). Simultaneous use of metformin and aspirin (OR = 0.44, 95 %CI: 0.17-1.12) was associated with lower MBD. Furthermore, in women who used metformin (OR = 0.23, 95% CI: 0.09-0.62) and aspirin (O R= 0.35, 95% CI: 0.17-0.72) for 2 to 5 years, MBD was significantly lower. However, after the adjustment of confounding factors, these associations were not statistically significant.
Conclusion: It seems metformin and aspirin intakes are associated with MBD. However, further studies with more sample size are needed.

Keywords: Aspirin, Metformin, Mammographic Breast density, Risk factor.
Full-Text [PDF 410 kb]   (184 Downloads)    
Type of Study: Original Article | Subject: Oncology
Received: 2022/08/27 | Accepted: 2022/11/5 | Published: 2023/09/15
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Eslami B, Omranipour R, Aryan A, Bayani L, Abedi M, Alipour S. Association of metformin and aspirin intake with mammographic breast density: a cross-sectional study. Caspian J Intern Med 2023; 14 (4) :741-745
URL: http://caspjim.com/article-1-3636-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 4 (Autumn 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 39 queries by YEKTAWEB 4624